60 related articles for article (PubMed ID: 16323137)
1. Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection.
Dai CY; Chuang WL; Chang WY; Chen SC; Lee LP; Hsieh MY; Hou NJ; Lin ZY; Huang JF; Hsieh MY; Wang LY; Yu ML
J Infect Dis; 2006 Jan; 193(1):98-101. PubMed ID: 16323137
[TBL] [Abstract][Full Text] [Related]
2. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C.
Rosen HR; McHutchison JG; Conrad AJ; Lentz JJ; Marousek G; Rose SL; Zaman A; Taylor K; Chou S
Am J Gastroenterol; 2002 Mar; 97(3):714-20. PubMed ID: 11922568
[TBL] [Abstract][Full Text] [Related]
4. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K
J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370
[TBL] [Abstract][Full Text] [Related]
5. Associations of tumour necrosis factor alpha promoter polymorphisms at position -308 and -238 with clinical characteristics of chronic hepatitis C.
Dai CY; Chuang WL; Lee LP; Chen SC; Hou NJ; Lin ZY; Hsieh MY; Hsieh MY; Wang LY; Chang WY; Yu ML
J Viral Hepat; 2006 Nov; 13(11):770-4. PubMed ID: 17052277
[TBL] [Abstract][Full Text] [Related]
6. HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C.
Romero-Gómez M; González-Escribano MF; Torres B; Barroso N; Montes-Cano MA; Sánchez-Muñoz D; Núñez-Roldan A; Aguilar-Reina J
Am J Gastroenterol; 2003 Jul; 98(7):1621-6. PubMed ID: 12873589
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms in the interferon-gamma gene at position +874 in patients with chronic hepatitis C treated with high-dose interferon-alpha and ribavirin.
Dai CY; Chuang WL; Chang WY; Chen SC; Lee LP; Hsieh MY; Hou NJ; Lin ZY; Hsieh MY; Wang LY; Yu ML
Antiviral Res; 2005 Aug; 67(2):93-7. PubMed ID: 16051377
[TBL] [Abstract][Full Text] [Related]
8. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
[TBL] [Abstract][Full Text] [Related]
9. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
[TBL] [Abstract][Full Text] [Related]
10. Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection.
Wietzke-Braun P; Maouzi AB; Mänhardt LB; Bickeböller H; Ramadori G; Mihm S
Eur J Gastroenterol Hepatol; 2006 Sep; 18(9):991-7. PubMed ID: 16894313
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in the IFNAR1 gene in patients with chronic hepatitis C: outcome of combined IFN-alpha therapy.
Tena-Tomás C; Pedroso ML; de Messias-Reason IJ; Kremsner PG; Kun JF
Eur Cytokine Netw; 2007 Sep; 18(3):136-41. PubMed ID: 17823081
[TBL] [Abstract][Full Text] [Related]
13. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
[TBL] [Abstract][Full Text] [Related]
14. A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1B.
Murayama M; Katano Y; Nakano I; Ishigami M; Hayashi K; Honda T; Hirooka Y; Itoh A; Goto H
J Med Virol; 2007 Jan; 79(1):35-40. PubMed ID: 17133546
[TBL] [Abstract][Full Text] [Related]
15. Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection.
Mueller T; Mas-Marques A; Sarrazin C; Wiese M; Halangk J; Witt H; Ahlenstiel G; Spengler U; Goebel U; Wiedenmann B; Schreier E; Berg T
J Hepatol; 2004 Oct; 41(4):652-8. PubMed ID: 15464247
[TBL] [Abstract][Full Text] [Related]
16. Response to combination therapy with interferon alfa-2a and ribavirin in chronic hepatitis C according to a TNF-alpha promoter polymorphism.
Schiemann U; Glas J; Török P; Simperl C; Martin K; König A; Schmidt F; Schaefer M; Folwaczny C
Digestion; 2003; 68(1):1-4. PubMed ID: 12949432
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor alpha promoter polymorphisms at position -308 in Taiwanese chronic hepatitis C patients treated with interferon-alpha.
Yu ML; Dai CY; Chiu CC; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chen CJ; Chuang WL; Chang WY
Antiviral Res; 2003 Jun; 59(1):35-40. PubMed ID: 12834858
[TBL] [Abstract][Full Text] [Related]
18. Ethnic differences in polymorphisms of tumor necrosis factor-alpha, interleukin-10, and transforming growth factor-beta1 genes in patients with chronic hepatitis C virus infection.
Zein NN; Germer JJ; El-Zayadi AR; Vidigal PG
Am J Trop Med Hyg; 2004 Apr; 70(4):434-7. PubMed ID: 15100460
[TBL] [Abstract][Full Text] [Related]
19. Effect of interferon therapy on fatty acid saturation index in hepatitis C virus infection.
Abdel Aziz MT; Abdel-Ghaffar Y; Fouad HH; Abdel Aziz DM; el-Magd AA
East Mediterr Health J; 2001; 7(4-5):779-86. PubMed ID: 15332779
[TBL] [Abstract][Full Text] [Related]
20. The -670A > G polymorphism in the promoter region of the FAS gene is associated with necrosis in periportal areas in patients with chronic hepatitis C.
Aguilar-Reina J; Ruiz-Ferrer M; Pizarro MA; Antiñolo G
J Viral Hepat; 2005 Nov; 12(6):568-73. PubMed ID: 16255757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
